APO-15 is a phosphatidylserine-binding fluorescent probe and apoptosis imaging reagent. APO-15 exhibits high chemical stability under proteolytic and oxidative conditions, enables quantification and imaging of drug-induced apoptosis in preclinical mouse models, and is applicable to fixed tissue samples and multiple in vivo administration routes (Ex = 488 nm; Em = 525 nm). APO-15 can be used in studies related to acute lung injury and breast cancer [1].
In Vivo, APO-15 (5 μM; intratracheal; single administration) enables in vivo detection and quantification of drug-induced apoptosis in mouse ALI models, with 29% of CD45+Ly6G+ neutrophils staining positive in BALF from LPS + CDKi-treated mice and 90 positive cells per 0.25 μm2 section in lung tissue[1]. APO-15 (5 μM; i.v.; single administration) detects cisplatin-induced apoptosis in mouse MMTV-PyMT breast cancer tumors, with signal co-localizing with the apoptotic marker cleaved caspase-3[1].
In Vitro, Apo-15 (50 μM; 24 h) exhibits high chemical stability under proteolytic, oxidative, and physiological buffer conditions, with >95% of the peptide remaining intact after 24 h exposure[1]. Apo-15 (100 nM; 10 min, 10 min at room temperature) competes with AF647-Annexin V for binding sites on apoptotic human neutrophils, confirming PS as its molecular target[1]. Apo-15 (100 nM; 10 min at room temperature) binding to apoptotic human cells is dependent on externalized PS, as it fails to stain apoptotic cells that cannot translocate PS to the outer membrane[1]. Apo-15 (100 nM; 15 min, 1000 s) enables wash-free, real-time imaging of apoptotic progression in live human lymphoid cells, with rapid fluorescence activation upon PS exposure[1].
References:
[1]. Barth ND, et al. A fluorogenic cyclic peptide for imaging and quantification of drug-induced apoptosis. Nat Commun. 2020;11(1):4027. Published 2020 Aug 12.
In Vivo, APO-15 (5 μM; intratracheal; single administration) enables in vivo detection and quantification of drug-induced apoptosis in mouse ALI models, with 29% of CD45+Ly6G+ neutrophils staining positive in BALF from LPS + CDKi-treated mice and 90 positive cells per 0.25 μm2 section in lung tissue[1]. APO-15 (5 μM; i.v.; single administration) detects cisplatin-induced apoptosis in mouse MMTV-PyMT breast cancer tumors, with signal co-localizing with the apoptotic marker cleaved caspase-3[1].
In Vitro, Apo-15 (50 μM; 24 h) exhibits high chemical stability under proteolytic, oxidative, and physiological buffer conditions, with >95% of the peptide remaining intact after 24 h exposure[1]. Apo-15 (100 nM; 10 min, 10 min at room temperature) competes with AF647-Annexin V for binding sites on apoptotic human neutrophils, confirming PS as its molecular target[1]. Apo-15 (100 nM; 10 min at room temperature) binding to apoptotic human cells is dependent on externalized PS, as it fails to stain apoptotic cells that cannot translocate PS to the outer membrane[1]. Apo-15 (100 nM; 15 min, 1000 s) enables wash-free, real-time imaging of apoptotic progression in live human lymphoid cells, with rapid fluorescence activation upon PS exposure[1].
References:
[1]. Barth ND, et al. A fluorogenic cyclic peptide for imaging and quantification of drug-induced apoptosis. Nat Commun. 2020;11(1):4027. Published 2020 Aug 12.